Resources realigned to focus primarily on in vivo macrophage engineering platform for fibrosis, oncology and autoimmune disease therapies Development of CT-0525 to be discontinued; workforce reduced by 34% PHILADELPHIA , Dec. 9, 2024 /PRNewswire/ -- Carisma Therapeutics Inc. (Nasdaq: CARM ) ("Carisma" or the "Company"), a leader in macrophage-focused therapeutics, today announced a strategic reprioritization of its pipeline,... Read More

PHILADELPHIA , Nov. 27, 2024 /PRNewswire/ -- Carisma Therapeutics Inc. (Nasdaq: CARM) ("Carisma" or the "Company"), a clinical-stage biopharmaceutical company focused on discovering and developing innovative immunotherapies, today announced that Steven Kelly , President and Chief Executive Officer, will participate in a fireside chat at the 7 th Annual Evercore ISI HealthCONx Conference on Thursday, December 5 th at 9:35 am... Read More

New preclinical results support the anti-fibrotic potential of engineered macrophages in multiple fibrosis models Engineered TIM4-expressing macrophages correct defective efferocytosis in MASH, demonstrating potent anti-fibrotic activity PHILADELPHIA , Nov. 17, 2024 /PRNewswire/ -- Carisma Therapeutics Inc. (Nasdaq: CARM) ("Carisma" or the "Company"), a clinical-stage biopharmaceutical company focused on discovering and... Read More

New findings showcase the potential of in vivo CAR-M technology as an effective, off-the-shelf treatment for hepatocellular carcinoma (HCC) PHILADELPHIA , Nov. 8, 2024 /PRNewswire/ -- Carisma Therapeutics Inc. (Nasdaq: CARM) ("Carisma" or the "Company"), a clinical-stage biopharmaceutical company focused on discovering and developing innovative immunotherapies, today announced positive pre-clinical data on its anti-GPC3 in... Read More

Initial results from the Phase 1 study of CT-0525, lead product candidate, expected in the first quarter of 2025 Nomination of a development candidate for liver fibrosis program expected in the first quarter of 2025 New preclinical efficacy data from the anti-GPC3 in vivo CAR-M therapy to be presented on November 8 at SITC 2024 Annual Meeting New preclinical efficacy data in liver fibrosis to be presented on November 17 at... Read More

Pre-clinical data demonstrate robust anti-tumor activity and a novel off-the-shelf approach for GPC3+ solid tumors PHILADELPHIA , Nov. 5, 2024 /PRNewswire/ -- Carisma Therapeutics Inc. (Nasdaq: CARM) ("Carisma" or the "Company"), a clinical-stage biopharmaceutical company focused on discovering and developing innovative immunotherapies, today announced the upcoming presentation of new pre-clinical data on its anti-GPC3 in... Read More

Appointment of Sohanya Cheng Resignation of Michael Torok PHILADELPHIA , Oct. 30, 2024 /PRNewswire/ -- Carisma Therapeutics Inc. (Nasdaq: CARM) ("Carisma" or the "Company"), a clinical-stage biopharmaceutical company focused on discovering and developing innovative immunotherapies, today announced the appointment of Sohanya Cheng, MBA to the Company's Board of Directors, effective October 31, 2024 . Additionally, Michael... Read More

PHILADELPHIA , Oct. 4, 2024 /PRNewswire/ -- Carisma Therapeutics Inc. (Nasdaq: CARM) ("Carisma" or the "Company"), a clinical-stage biopharmaceutical company focused on discovering and developing innovative immunotherapies, today announced its upcoming poster presentations at the Society for Immunotherapy of Cancer (SITC), taking place in Houston, Texas , November 6 -10, 2024 . Details on the poster presentations at SITC... Read More

Building on successful pre-clinical in vivo CAR-M data in oncology, the companies will develop in vivo CAR-M for autoimmune diseases Moderna nominated two autoimmune disease targets under the collaboration Carisma is eligible to receive milestones and royalty payments PHILADELPHIA , Sept. 10, 2024 /PRNewswire/ -- Carisma Therapeutics Inc. (Nasdaq: CARM) ("Carisma" or the "Company"), a clinical stage biopharmaceutical company... Read More

PHILADELPHIA , Sept. 3, 2024 /PRNewswire/ -- Carisma Therapeutics Inc . (Nasdaq: CARM) ("Carisma" or the "Company"), a clinical-stage biopharmaceutical company focused on discovering and developing innovative immunotherapies, today announced that Steven Kelly, President and Chief Executive Officer, will participate in the following upcoming conferences: Baird 2024 Global Healthcare Conference Tuesday, September 10 at 12:50... Read More

Initial data for CT-0525, lead product candidate for anti-HER2 program, expected by year-end 2024 Nomination of a development candidate for liver fibrosis program expected in the first quarter of 2025 Nominated first in vivo CAR-M development candidate targeting Glypican-3 to treat hepatocellular carcinoma under the Moderna Collaboration in the second quarter of 2024 Cash and cash equivalents of $40.4 million and $2.0... Read More

PHILADELPHIA , Aug. 6, 2024 /PRNewswire/ -- Carisma Therapeutics Inc. (Nasdaq: CARM) ("Carisma" or the "Company"), a clinical-stage biopharmaceutical company focused on discovering and developing innovative immunotherapies, today announced its upcoming poster presentation at the American Association for the Study of Liver Diseases (AASLD) The Liver Meeting® 2024, taking place in San Diego, California , November 15 – 19,... Read More

Company appoints renowned key opinion leaders in liver fibrosis, Scott Friedman , MD, and Ira Tabas , MD, PhD PHILADELPHIA , Aug. 6, 2024 /PRNewswire/ -- Carisma Therapeutics Inc. (Nasdaq: CARM) ("Carisma" or the "Company"), a clinical-stage biopharmaceutical company focused on discovering and developing innovative immunotherapies, today announced the appointment of Dr. Scott Friedman and Dr. Ira Tabas to its Scientific... Read More

Appointment of David Scadden , M.D. and Marella Thorell Resignation of Regina Hodits and Björn Odlander PHILADELPHIA , July 1, 2024 /PRNewswire/ -- Carisma Therapeutics Inc. (Nasdaq: CARM) ("Carisma" or the "Company"), a clinical-stage biopharmaceutical company focused on discovering and developing innovative immunotherapies, today announced the appointment of Marella Thorell and David Scadden , M.D., to the Company's Board... Read More

Development Candidate targets Glypican-3 for the treatment of solid tumors, including hepatocellular carcinoma Nomination triggers a $2 million milestone payment to Carisma PHILADELPHIA , June 27, 2024 /PRNewswire/ -- Carisma Therapeutics Inc. (Nasdaq: CARM) ("Carisma" or the "Company"), a clinical stage biopharmaceutical company focused on discovering and developing innovative immunotherapies, today announced the nomination... Read More

Fast Track designation highlights potential for CT-0525 to address unmet need for patients with solid tumors Initial Phase 1 data expected by year-end 2024 PHILADELPHIA , June 25, 2024 /PRNewswire/ -- Carisma Therapeutics Inc. (Nasdaq: CARM) ("Carisma" or the "Company"), a clinical stage biopharmaceutical company focused on discovering and developing innovative immunotherapies, announced today that the U.S. Food and Drug... Read More

PHILADELPHIA , June 25, 2024 /PRNewswire/ -- Carisma Therapeutics Inc. (Nasdaq: CARM) ("Carisma" or the "Company"), a clinical-stage biopharmaceutical company focused on discovering and developing innovative immunotherapies, today announced that Steven Kelly , President and Chief Executive Officer, will participate in a fireside chat at the Stifel 2024 Cell Therapy Forum on Tuesday, July 9 th at 9:10 am ET . An audio webcast... Read More

Meeting will be reconvened on Friday, June 14, 2024 at 10:00 a.m. Eastern Time PHILADELPHIA , June 13, 2024 /PRNewswire/ -- Carisma Therapeutics Inc. (Nasdaq: CARM) ("Carisma" or the "Company"), a clinical-stage biopharmaceutical company focused on discovering and developing innovative immunotherapies, today announced that the Company's virtual annual meeting of stockholders held on June 13, 2024 was convened and adjourned,... Read More

PHILADELPHIA , May 30, 2024 /PRNewswire/ -- Carisma Therapeutics Inc. (Nasdaq: CARM) ("Carisma" or the "Company"), a clinical-stage biopharmaceutical company focused on discovering and developing innovative immunotherapies, today announced that Steven Kelly , President and Chief Executive Officer, will participate in a fireside chat at the Jefferies Global Healthcare Conference on Thursday, June 6 th at 3:00 pm ET . An audio... Read More

CT-0525 is the first CAR-Monocyte to be evaluated in humans in the solid tumor setting Initial data expected by year-end 2024 PHILADELPHIA , May 16, 2024 /PRNewswire/ -- Carisma Therapeutics Inc. (Nasdaq: CARM) ("Carisma" or the "Company"), a clinical stage biopharmaceutical company focused on discovering and developing innovative immunotherapies, today announced that the first patient was dosed in its Phase 1 clinical trial... Read More

Announced CT-0525 as lead product candidate for anti-HER2 program; initial data expected by year-end 2024 Presented preclinical proof of concept data in liver fibrosis at ASGCT; expects to nominate a development candidate in the first quarter of 2025 Presented Regimen Level 1 data from Phase 1 sub-study utilizing CT-0508 in combination with pembrolizumab at AACR; expects to report Regimen Level 2 data in second quarter of... Read More

Novel anti-fibrotic engineered macrophage therapy reduced liver fibrosis in preclinical models Development candidate nomination expected in the first quarter of 2025 PHILADELPHIA , May 8, 2024 /PRNewswire/ -- Carisma Therapeutics Inc. (Nasdaq: CARM) ("Carisma" or the "Company"), a clinical-stage biopharmaceutical company focused on discovering and developing innovative immunotherapies, today announced new data demonstrating... Read More

PHILADELPHIA , May 6, 2024 /PRNewswire/ -- Carisma Therapeutics Inc. (Nasdaq: CARM) ("Carisma" or the "Company"), a clinical-stage biopharmaceutical company focused on discovering and developing innovative immunotherapies, today announced that Steven Kelly , President and Chief Executive Officer, will participate in a fireside chat at The Citizens JMP Life Sciences Conference on Monday, May 13 th at 12:00 pm ET . An audio... Read More

Industry veteran with expertise in oncology and immuno-oncology and a strong track record of advancing programs through clinical development PHILADELPHIA , May 2, 2024 /PRNewswire/ -- Carisma Therapeutics Inc. (Nasdaq: CARM) ("Carisma" or the "Company"), a clinical-stage biopharmaceutical company focused on discovering and developing innovative immunotherapies, today announced the appointment of Eugene P. Kennedy , M.D.,... Read More

PHILADELPHIA , April 24, 2024 /PRNewswire/ -- Carisma Therapeutics Inc. (Nasdaq: CARM) ("Carisma" or the "Company"), a clinical-stage biopharmaceutical company focused on discovering and developing innovative immunotherapies, today announced its upcoming presentation at the American Society of Clinical Oncology (ASCO) 2024 Annual Meeting taking place from May 31- June 4, 2024 , in Chicago, IL. Details on the poster... Read More

Preclinical data highlights the potential of engineered macrophage cell therapy as a treatment for liver and lung fibrosis Novel Redirected Soluble Modulator technology has demonstrated the potential to enhance immune receptor signaling PHILADELPHIA , April 22, 2024 /PRNewswire/ -- Carisma Therapeutics Inc. (Nasdaq: CARM) ("Carisma" or the "Company"), a clinical-stage biopharmaceutical company focused on discovering and... Read More

PHILADELPHIA , April 3, 2024 /PRNewswire/ -- Carisma Therapeutics Inc. (Nasdaq: CARM) ("Carisma" or the "Company"), a clinical-stage biopharmaceutical company focused on discovering and developing innovative immunotherapies, today announced that it will present at the following upcoming conferences: Needham 23 rd Annual Virtual Healthcare Conference Steven Kelly , President and Chief Executive Officer, will give a corporate... Read More

Company to prioritize CT-0525 as its anti-HER2 CAR-M product candidate and will cease further development of CT-0508 Other prioritized pipeline programs include the Company's in vivo CAR-M collaboration with Moderna, and research programs including fibrosis Cash and cash equivalents of $77.6 million as of December 31, 2023 , combined with a restructuring of operations, including pausing development of CT-1119, expected to... Read More

Appointment of John Hohneker, M.D. Resignation of Chidozie Ugwumba PHILADELPHIA , April 1, 2024 /PRNewswire/ -- Carisma Therapeutics Inc. (Nasdaq: CARM) ("Carisma" or the "Company"), a clinical-stage biopharmaceutical company focused on discovering and developing innovative immunotherapies, today announced the appointment of John Hohneker , M.D. to the Board of Directors of the Company, effective April 1, 2024.... Read More

PHILADELPHIA , March 21, 2024 /PRNewswire/ -- Carisma Therapeutics Inc. (Nasdaq: CARM) ("Carisma" or the "Company"), a clinical-stage biopharmaceutical company focused on discovering and developing innovative immunotherapies, today announced its upcoming presentations at the American Association for Cancer Research (AACR) Annual Meeting taking place from April 5-10, 2024 , in San Diego, California . The poster presentation... Read More

PHILADELPHIA , Feb. 28, 2024 /PRNewswire/ -- Carisma Therapeutics Inc. (Nasdaq: CARM) ("Carisma" or the "Company"), a clinical-stage biopharmaceutical company focused on discovering and developing innovative immunotherapies, today announced that Steven Kelly , President and Chief Executive Officer, will participate in the TD Cowen 44 th Annual Health Care Conference on Wednesday, March 6 th at 2:50 pm ET . An audio webcast... Read More

PHILADELPHIA , Dec. 21, 2023 /PRNewswire/ -- Carisma Therapeutics Inc. (Nasdaq: CARM) ("Carisma" or the "Company"), a clinical-stage biopharmaceutical company focused on discovering and developing innovative immunotherapies, today announced that the company will present at the 42 nd Annual J.P. Morgan Healthcare Conference on Thursday, January 11, 2024 . Steven Kelly , President and Chief Executive Officer, will make a... Read More

First lead candidate to address a solid tumor indication with significant unmet medical need Supportive pre-clinical proof of concept data reported at SITC 2023 that demonstrated feasibility, tolerability and early efficacy of in vivo CAR-M therapy utilizing mRNA/LNPs in solid tumors PHILADELPHIA , Dec. 14, 2023 /PRNewswire/ -- Carisma Therapeutics Inc. (Nasdaq: CARM) ("Carisma" or the "Company"), a clinical-stage... Read More

CT-0525 is the first CAR-Monocyte to be evaluated in humans in the solid tumor setting First patient expected to be treated in the first half of 2024 PHILADELPHIA , Nov. 28, 2023 /PRNewswire/ -- Carisma Therapeutics Inc. (Nasdaq: CARM) ("Carisma" or the "Company"), a clinical stage biopharmaceutical company focused on discovering and developing innovative immunotherapies, today announced the clearance of its Investigational... Read More

PHILADELPHIA , Nov. 22, 2023 /PRNewswire/ -- Carisma Therapeutics Inc. (Nasdaq: CARM) ("Carisma" or the "Company"), a clinical-stage biopharmaceutical company focused on discovering and developing innovative immunotherapies, today announced that Steven Kelly , President and Chief Executive Officer, will participate in a fireside chat at the 6 th Annual Evercore ISI HealthCONx Conference on Wednesday, November 29 at 2:35 pm... Read More

Presented updated data from Phase 1 clinical trial of CT-0508 at CAR-TCR Summit, further supporting CAR-M safety, feasibility and mechanism of action Selected clinical candidate for CT-1119, an anti-mesothelin CAR-Monocyte Presented pre-clinical proof of concept data of in vivo CAR-M, from the Company's collaboration with Moderna, at SITC Cash, cash equivalents and marketable securities of $94.1 million expected to fund... Read More

Data demonstrate feasibility, tolerability, and early efficacy of mRNA/LNP in vivo CAR-M therapy in pre-clinical models of metastatic solid tumors Proof of concept achieved for platform under the Moderna collaboration "In vivo CAR-M: Redirecting endogenous myeloid cells with mRNA for cancer immunotherapy" to be presented Friday, November 3, 2023 , at 11:30 am PT PHILADELPHIA , Oct. 31, 2023 /PRNewswire/ -- Carisma... Read More

Late-breaking abstract to be presented on November 3 rd at 11:30 am PT highlighting pre-clinical data with Moderna Two additional pre-clinical data abstracts highlighting next-generation enhancements to Carisma's cell therapy platform to be shared PHILADELPHIA , Oct. 25, 2023 /PRNewswire/ -- Carisma Therapeutics Inc. (Nasdaq: CARM) ("Carisma" or the "Company"), a clinical-stage biopharmaceutical company focused on... Read More

PHILADELPHIA , Sept. 5, 2023 /PRNewswire/ -- Carisma Therapeutics Inc. (Nasdaq: CARM) ("Carisma" or the "Company"), a clinical-stage biopharmaceutical company focused on discovering and developing innovative immunotherapies, today announced that it will present at several upcoming investor conferences, including: H.C. Wainwright 25th Annual Global Investment Conference Steven Kelly , President and Chief Executive Officer,... Read More

Group 2 data available to date support primary safety and feasibility endpoints of single-day bolus dosing of CT-0508 New translational analyses combining group 1 & group 2 continue to support CAR-M mechanism of action, demonstrating a correlation between biomarkers and best overall response PHILADELPHIA , Sept. 1, 2023 /PRNewswire/ -- Carisma Therapeutics Inc. (Nasdaq: CARM) ("Carisma" or the "Company"), a clinical stage... Read More

PHILADELPHIA , Aug. 24, 2023 /PRNewswire/ -- Carisma Therapeutics Inc. (Nasdaq: CARM) ("Carisma" or the "Company"), a clinical stage biopharmaceutical company focused on discovering and developing innovative immunotherapies, today announced that the Company will present at two healthcare industry conferences in September 2023 . These conferences include: 8 th Annual CAR-TCR Summit Michael Klichinsky , PharmD, PhD, Co-Founder... Read More

Dosed first patient in Phase 1 clinical trial of CT-0508 in combination with KEYTRUDA® (pembrolizumab) in patients with HER2-overexpressing solid tumors Nominated additional oncology target as part of the Company's collaboration with Moderna to develop in-vivo targeted CAR-M therapies Cash, cash equivalents and marketable securities of $117.1 million expected to fund company through 2024 PHILADELPHIA , Aug. 10, 2023... Read More

Study is designed to evaluate the potential for a synergistic effect of CAR-M therapy in combination with KEYTRUDA ® PHILADELPHIA , June 28, 2023 /PRNewswire/ -- Carisma Therapeutics Inc. (Nasdaq: CARM) ("Carisma" or the "Company"), a clinical stage biopharmaceutical company focused on discovering and developing innovative immunotherapies, announced that the first patient has been dosed in its Phase I clinical trial that... Read More

PHILADELPHIA , June 26, 2023 /PRNewswire/ -- Carisma Therapeutics Inc. (Nasdaq: CARM) ("Carisma" or the "Company"), a clinical-stage biopharmaceutical company focused on discovering and developing innovative immunotherapies, today announced that the Company will join the Russell 2000 ® , Russell 3000 ® and Russell Microcap ® Indexes following the conclusion of the 2023 Russell indexes annual reconstitution, effective upon... Read More

PHILADELPHIA , May 30, 2023 /PRNewswire/ -- Carisma Therapeutics Inc. (Nasdaq: CARM) ("Carisma" or the "Company"), a clinical stage biopharmaceutical company focused on discovering and developing innovative immunotherapies, today announced that the Company will present at several healthcare industry conferences in June 2023 . These conferences include: 2023 American Society of Clinical Oncology (ASCO) Annual Meeting Yara... Read More

PHILADELPHIA , May 8, 2023 /PRNewswire/ -- Carisma Therapeutics Inc. (Nasdaq: CARM) ("Carisma" or the "Company"), a clinical-stage biopharmaceutical company focused on discovering and developing innovative immunotherapies, today announced that Steven Kelly , President and Chief Executive Officer, will present at the JMP Securities Life Sciences Conference on Monday, May 15 at 1:00 pm EDT in New York . A live webcast will be... Read More

PHILADELPHIA , May 5, 2023 /PRNewswire/ -- Carisma Therapeutics Inc. (Nasdaq: CARM) ("Carisma"), a clinical stage biopharmaceutical company focused on discovering and developing innovative immunotherapies, today announced that the company will present at several healthcare industry conferences in May 2023 . These conferences include: American Society of Gene & Cell Therapy (ASGCT) 26 th Annual Meeting 2023 Carisma is giving... Read More

CAMBRIDGE, Mass. / Mar 02, 2023 / Business Wire / Sesen Bio, Inc. (Nasdaq: SESN) (“Sesen Bio” or the “Company”), today announced that its stockholders have voted to approve all proposals, including the pending merger with Carisma Therapeutics Inc. (“Carisma”), at the Company’s Special Meeting of Stockholders (the “Special Meeting”) held earlier today. Dr. Thomas Cannell, President and Chief Executive Officer of Sesen Bio,... Read More

CAMBRIDGE, Mass. / Feb 21, 2023 / Business Wire / Sesen Bio, Inc. (Nasdaq: SESN) (“Sesen Bio” or the “Company”), today announced that leading independent proxy advisory firm Glass, Lewis & Co. (“Glass Lewis”) recommends that stockholders vote “FOR” all proposals, including the pending merger with Carisma Therapeutics Inc. (“Carisma”), in advance of the Company’s upcoming Special Meeting of Stockholders (the “Special... Read More

CAMBRIDGE, Mass. / Feb 16, 2023 / Business Wire / Sesen Bio, Inc. (Nasdaq: SESN) (“Sesen Bio” or the “Company”), today announced that Institutional Shareholder Services (“ISS”) recommends that stockholders vote “FOR” all proposals, including the pending merger with Carisma Therapeutics Inc. (“Carisma”), at the Company’s upcoming Special Meeting of Stockholders (the “Special Meeting”) scheduled for March 2, 2023. ISS is... Read More

CAMBRIDGE, Mass. / Feb 02, 2023 / Business Wire / Sesen Bio, Inc. (NASDAQ: SESN) today filed an investor presentation highlighting its value maximizing merger with Carisma Therapeutics Inc. (“Carisma”). The presentation can be found at www.SesenBioandCarisma.com . Highlights of the presentation include: The merger with Carisma delivers substantial and immediate value for Sesen Bio stockholders, which is meaningfully better... Read More

Company Remains Focused on Significant Benefits of Pending Merger with Carisma Delisting Notice Underscores Potential for Corporate Dissolution if Merger is not Approved by Stockholders CAMBRIDGE, Mass. / Jan 30, 2023 / Business Wire / Sesen Bio, Inc. (Nasdaq: SESN) (“Sesen Bio” or the “Company”) today announced that it has received notice from the Listing Qualifications Department of The Nasdaq Stock Market LLC (“Nasdaq”)... Read More

Company Calls Out Misrepresentations from Investor Group CAMBRIDGE, Mass. / Jan 26, 2023 / Business Wire / Sesen Bio, Inc. (Nasdaq: SESN) today issued the following statement reiterating the Company’s confidence in, and commitment to, the pending merger with Carisma Therapeutics Inc. (Carisma) in response to the release issued yesterday by Bradley Radoff and Michael Torok and their affiliates (collectively, the “Investor... Read More

Schedules March 2, 2023, Special Meeting of Stockholders to Vote on Merger Launches www.SesenBioandCarisma.com , Providing Additional Information for Stockholders Sesen Bio, Inc. (Nasdaq: SESN) today announced that it has filed definitive proxy materials with the U.S. Securities and Exchange Commission in connection with the Company’s pending merger with Carisma Therapeutics Inc. (Carisma), a privately held, clinical stage... Read More

Highlights Expected Special Cash Dividend of Approximately $70 Million, and Upside of CVR and Ownership of Combined Company Sesen Bio, Inc. (Nasdaq: SESN) today issued the following statement reiterating the Company’s confidence in, and commitment to, the pending merger with Carisma Therapeutics Inc. (Carisma) as the best path forward for stockholders. The Sesen Bio Board of Directors remains confident that the pending... Read More

Sesen Bio Stockholders Expected to Receive Approximately $70 Million Special Cash Dividend, an Increase from up to $25 Million Previously Announced Contingent Value Right to Include Proceeds of Vicineum and Other Preclinical Assets, in Addition to Previously Announced Proceeds of Roche Agreement Companies Provide Update on Engagement with Investor Group Sesen Bio, Inc. (Nasdaq: SESN) and Carisma Therapeutics Inc. (Carisma),... Read More